Originally published by our sister publication Infectious Disease Special Edition
HIV-associated wasting has declined with access to antiretrovirals (ARVs). However, weight gain and metabolic syndrome continue to increase across people with HIV.1 Access to more effective and tolerable ARVs has increased virologic suppression and immunologic recovery, leading to increased life span.1 The benefit of ARVs on morbidity and mortality outweighs the